DOCSLIB.ORG

The Raw Numbers of Prescribed Antidepressant Items by Class, from 1998 to 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Raw Numbers of Prescribed Antidepressant Items by Class, from 1998 to 2018 Figure S1 - The raw numbers of prescribed antidepressant items by class, from 1998 to 2018. MAOI = monoamine oxidase inhibitor, SNRI = selective serotonin-norepinephrine reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor. Figure S2 - The raw numbers of prescribed antidepressant items for the ten most commonly prescribed antidepressants (in 2018), from 1998 to 2018. Figure S3 - Practice level percentile charts for the proportions of the ten most commonly prescribed antidepressants (in 2018), prescribed between August 2010 and November 2019. Deciles are in blue, with median shown as a heavy blue line, and extreme percentiles are in red. Figure S4 - Practice level percentile charts for the proportions of specific MAOIs prescribed between August 2010 and November 2019. Deciles are in blue, with median shown as a heavy blue line, and extreme percentiles are in red. Figure S5 - CCG level heat map for the percentage proportions of MAOIs prescribed between December 2018 and November 2019. MAOI = monoamine oxidase inhibitor. Figure S6 - CCG level heat maps for the percentage proportions of paroxetine, dosulepin, and trimipramine prescribed between December 2018 and November 2019. Table S1 - Antidepressant drugs, by category. MAOI = monoamine oxidase inhibitor, SNRI = selective serotonin-norepinephrine reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor. Class Drug MAOI Isocarboxazid, moclobemide, phenelzine, tranylcypromine SNRI Duloxetine, venlafaxine SSRI Citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline Tricyclic Amitriptyline, amoxapine, clomipramine, dosulepin, doxepin, imipramine, lofepramine, nortriptyline, protriptyline, trimipramine Other Agomelatine, bupropion, flupentixol, maprotiline, mianserin, mirtazapine, nefazodone, oxitriptan, reboxetine, trazodone, tryptophan, vortioxetine Table S2 - Basic descriptive statistics For practice level class-speciFic proportions oF antidepressants prescribed between December 2018 and November 2019. IDR = interdecile range, IQR = interquartile range, MAOI = monoamine oxidase inhibitor, SNRI = selective serotonin- norepinephrine reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor. Standard Lowest Lower Upper Highest Mean Median IQR IDR deviation Decile quartile quartile Decile SSRI % 54.5 6.6 46.4 50.5 54.7 58.5 62.2 8.0 15.8 Tricyclic % 21.5 5.4 15.3 18.2 21.2 24.5 27.9 6.3 12.6 Other % 14.7 5.3 8.7 11.1 14.2 17.6 21.0 6.5 12.2 SNRI % 9.2 3.3 5.5 7.1 9.0 11.1 13.3 3.9 7.7 MAOI % 0.1 0.2 0 0 0 0 0.2 0 0.2 Table S3 - Practice level basic descriptive statistics For the proportions oF the ten most prescribed antidepressants (in 2018) prescribed between December 2018 and November 2019. IDR = interdecile range, IQR = interquartile range. Standard Lowest Lower Upper Highest Mean Median IQR IDR deviation decile quartile quartile decile Sertraline% 21.6 5.8 14.6 18.0 21.4 25.1 28.6 7.1 14.0 Citalopram % 20.0 6.1 12.6 15.8 19.7 23.8 27.8 8.0 15.2 Amitriptyline % 18.9 5.2 13.0 15.6 18.6 21.8 25.1 6.1 12.1 Mirtazapine % 12.9 4.9 7.5 9.6 12.4 15.5 18.6 5.8 11.1 Fluoxetine % 9.1 3.3 5.4 6.9 8.7 10.9 13.2 3.9 7.9 Venlafaxine % 6.0 2.6 3.1 4.3 5.8 7.5 9.3 3.2 6.2 Duloxetine % 3.2 2.0 1.1 1.8 2.8 4.1 5.7 2.3 4.6 Paroxetine % 1.9 1.3 0.7 1.2 1.7 2.4 3.3 1.3 2.6 Trazodone % 1.4 1.6 0 0.4 0.9 1.9 3.3 1.5 3.3 Escitalopram % 1.8 2.1 0.2 0.6 1.1 2.1 3.9 1.6 3.7 Table S4 - Practice level basic descriptive statistics For the proportions oF speciFic MAOIs prescribed between December 2018 and November 2019. IDR = interdecile range, IQR = interquartile range. Standard Lowest Lower Upper Highest Mean Median IQR IDR deviation decile quartile quartile decile Moclobemide % 0 0.1 0 0 0 0 0.1 0 0.1 Phenelzine % 0 0.1 0 0 0 0 0.1 0 0.1 Tranylcypromine % 0 0.1 0 0 0 0 0 0 0 Isocarboxazid % 0 0 0 0 0 0 0 0 0 Table S5 - Unadjusted and adjusted estimates for any practice-level prescribing of dosulepin and trimipramine from logistic regression analysis. CI = confidence interval, GP = general practitioner, IMD = Index of Multiple Deprivation, OR = odds ratio, QOF = Quality Outcomes Framework. Mean % of Unadjusted OR Adjusted OR dosulepin and (95% CI) (95% CI) trimipramine Proportion of 0 to 11.1 0.74 Reference Reference patients over 65 11.2 to 15.7 0.90 1.16 (1.13 to 1.18) 1.23 (1.20 to 1.26) 15.7 to 19.25 0.94 1.24 (1.21 to 1.26) 1.36 (1.33 to 1.40) 19.26 to 23.2 1.01 1.35 (1.33 to 1.38) 1.53 (1.49 to 1.57) 23.2 to 90.3 1.08 1.46 (1.43 to 1.48) 1.59 (1.55 to 1.64) Proportion of 15.7 to 44.4 0.85 Reference Reference patients with a long term health 44.4 to 49.7 0.97 1.15 (1.13 to 1.18) 1.06 (1.04 to 1.09) condition 49.7 to 53.9 0.93 1.11 (1.09 to 1.13) 0.99 (0.97 to 1.01) 53.9 to 58.6 0.99 1.15 (1.13 to 1.17) 1.02 (1.00 to 1.04) 58.6 to 100 0.94 1.09 (1.07 to 1.11) 0.98 (0.96 to 1.00) List size <4.3 0.95 Reference Reference (thousands) 4.3 to 6.4 0.91 0.98 (0.96 to 1.00) 0.98 (0.96 to 1.00) 6.4 to 8.8 0.96 1.01 (0.99 to 1.04) 1.01 (0.99 to 1.04) 8.8 to 12.0 0.94 1.01 (0.99 to 1.03) 1.04 (1.02 to 1.07) >12.0 0.91 0.98 (0.96 to 1.00) 1.04 (1.02 to 1.06) GPs per 1000 <3.6 0.91 Reference Reference patients 3.7 to 4.8 0.99 1.06 (1.05 to 1.08) 1.04 (1.03 to 1.06) 4.8 to 5.9 0.93 1.01 (0.99 to 1.03) 0.99 (0.97 to 1.01) 5.9 to 7.4 0.93 0.99 (0.97 to 1.00) 0.98 (0.96 to 1.00) >7.4 0.92 0.98 (0.96 to 0.99) 0.94 (0.92 to 0.95) Rurality Rural village and 0.93 Reference Reference dispersed Rural town and 0.85 0.94 (0.91 to 0.96) 0.95 (0.89 to 1.01) fringe Urban city and town 0.87 0.95 (0.94 to 0.96) 0.87 (0.84 to 0.90) Urban minor 1.05 1.11 (1.09 to 1.12) 0.92 (0.89 to 0.95) conurbation Urban major 1.28 1.35 (1.32 to 1.39) 1.11 (1.06 to 1.16) conurbation IMD Least deprived 1.05 Reference Reference | 1.04 1.00 (0.99 to 1.02) 1.01 (0.99 to 1.02) | 0.88 0.86 (0.85 to 0.87) 0.94 (0.92 to 0.96) | 0.84 0.81 (0.79 to 0.82) 0.91 (0.89 to 0.93) Most deprived 0.86 0.82 (0.81 to 0.84) 0.94 (0.91 to 0.96) QOF sCore 160-532 0.95 Reference Reference 532-546 0.96 1.01 (0.99 to 1.02) 1.04 (1.02 to 1.06) 546-554 0.92 0.98 (0.96 to 0.99) 1.00 (0.98 to 1.01) 554-558 0.95 0.97 (0.96 to 0.99) 0.97 (0.95 to 0.98) 558-559 0.90 0.96 (0.94 to 0.97) 0.93 (0.92 to 0.95) .
Load more

Recommended publications
  • Product Monograph
    PRODUCT MONOGRAPH PrFLUANXOL® Flupentixol Tablets (as flupentixol dihydrochloride) 0.5 mg, 3 mg, and 5 mg PrFLUANXOL® DEPOT Flupentixol Decanoate Intramuscular Injection 2% and 10% flupentixol decanoate Antipsychotic Agent Lundbeck Canada Inc. Date of Revision: 2600 Alfred-Nobel December 12th, 2017 Suite 400 St-Laurent, QC H4S 0A9 Submission Control No : 209135 Page 1 of 35 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................21
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Depot Antipsychotic Injections
    Mental Health Services Good Practice Statement For The Use Of DEPOT & LONG ACTING ANTIPSYCHOTIC INJECTIONS Date of Revision: February 2020 Approved by: Mental Health Prescribing Management Group Review Date: CONSULTATION The document was sent to Community Mental Health teams, Pharmacy and the Psychiatric Advisory Committee for comments prior to completion. KEY DOCUMENTS When reading this policy please consult the NHS Consent Policy when considering any aspect of consent National Institute for Clinical Excellence CG178 (2014), Psychosis and schizophrenia in adults: prevention and management NHS Lothian (2011), Depot Antipsychotic Guidance, Maudsley (2015), Prescribing Guidelines in Psychiatry 12th edition. UKPPG (2009) Guidance on the Administration to Adults of Oil based Depot and other Long Acting Intramuscular Antipsychotic Injections Summary of Product Characteristics for: Clopixol (Zuclopethixol Decanoate) Flupenthixol Decanoate Haldol (Haloperidol Decanoate) Risperdal Consta Xeplion (Paliperidone Palmitate) ZypAdhera (Olanzapine Embonate) Abilify Maintena (Aripiprazole) 1 CONTENTS REFERENCES/KEY DOCUMENTS …………………………………………………………… 1 INTRODUCTION …………………………………………………………………………………. 3 SCOPE …………………………………………………………………………………………….. 3 DEFINITIONS ……………………………………………………………………………………... 3 CHOICE OF DRUG AND DOSAGE SELECTION ……………………………………………. 3 SIDE EFFECTS ……………………………………………………………….………………….. 5 PRESCRIBING …………………………………………………………………………………… 5 ADMINISTRATION ………………………………………………………………………………. 7 RECORDING ADMINISTRATION ……………………………………………………………… 7
    [Show full text]
  • Deanxit SPC.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Deanxit film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Flupentixol 0.5 mg (as 0.584 mg flupentixol dihydrochloride) Melitracen 10 mg (as 11.25 mg melitracen hydrochloride) Excipients with known effect: Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. Round, biconvex, cyclamen, film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Anxiety Depression Asthenia. Neurasthenia. Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. 4.2 Posology and method of administration Posology Adults Usually 2 tablets daily: morning and noon. In severe cases the morning dose may be increased to 2 tablets. The maximum dose is 4 tablets daily. Older people (> 65 years) 1 tablet in the morning. In severe cases 1 tablet in the morning and 1 at noon. Maintenance dose: Usually 1 tablet in the morning. SPC Portrait-REG_00051968 20v038 Page 1 of 10 In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Paediatric population Children and adolescents (<18 years) Deanxit is not recommended for use in children and adolescents due to lack of data on safety and efficacy. Reduced renal function Deanxit can be given in the recommended doses. Reduced liver function Deanxit can be given in the recommended doses. Method of administration The tablets are swallowed with water. 4.3 Contraindications Hypersensitivity to flupentixol and melitracen or to any of the excipients listed in section 6.1.
    [Show full text]
  • Fatal Toxicity of Antidepressant Drugs in Overdose
    BRITISH MEDICAL JOURNAL VOLUME 295 24 OCTOBER 1987 1021 Br Med J (Clin Res Ed): first published as 10.1136/bmj.295.6605.1021 on 24 October 1987. Downloaded from PAPERS AND SHORT REPORTS Fatal toxicity of antidepressant drugs in overdose SIMON CASSIDY, JOHN HENRY Abstract dangerous in overdose, thus meriting investigation of their toxic properties and closer consideration of the circumstances in which A fatal toxicity index (deaths per million National Health Service they are prescribed. Recommendations may thus be made that prescriptions) was calculated for antidepressant drugs on sale might reduce the number offatalities. during the years 1975-84 in England, Wales, and Scotland. The We used national mortality statistics and prescription data tricyclic drugs introduced before 1970 had a higher index than the to compile fatal toxicity indices for the currently available anti- mean for all the drugs studied (p<0-001). In this group the depressant drugs to assess the comparative safety of the different toxicity ofamitriptyline, dibenzepin, desipramine, and dothiepin antidepressant drugs from an epidemiological standpoint. Owing to was significantly higher, while that ofclomipramine, imipramine, the nature of the disease these drugs are particularly likely to be iprindole, protriptyline, and trimipramine was lower. The mono- taken in overdose and often cause death. amine oxidase inhibitors had intermediate toxicity, and the antidepressants introduced since 1973, considered as a group, had significantly lower toxicity than the mean (p<0-001). Ofthese newer drugs, maprotiline had a fatal toxicity index similar to that Sources ofinformation and methods of the older tricyclic antidepressants, while the other newly The statistical sources used list drugs under their generic and proprietary http://www.bmj.com/ introduced drugs had lower toxicity indices, with those for names.
    [Show full text]
  • 020592Orig1s040s041
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 020592Orig1s040s041 MEDICAL REVIEW(S) M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: July 18, 2008 FROM: Ni A. Khin, M.D. Team Leader Division of Psychiatry Products, HFD-130 TO: NDA 20-592/SE5-040 (bipolar I disorder, acute mania) NDA 20-592/SE5-041 (schizophrenia) (This overview should be filed with the 02-05-2008 submission in response to the Agency’s Approvable Letter dated 04-30-2007) SUBJECT: Recommendation of an approvable action for use of Zyprexa (olanzapine) in the treatment of 1) Bipolar I disorder, Mania, and 2) schizophrenia in Adolescents. 1. BACKGROUND Zyprexa (olanzapine) is an atypical antipsychotic agent, approved in the U.S. for treatment of schizophrenia and bipolar disorder, mania or mixed episodes, as monotherapy (both acute and maintenance) or combination therapy in adults. It is available as oral 2.5, 5, 10, 15, or 20 mg strength tablets; 5, 10, 15, or 20 mg oral disintegrating tablets (Zydis). The target dose for adults with schizophrenia is 10 mg/day. Zyprexa intramuscular injection (10 mg) is indicated for agitation associated with schizophrenia and Bipolar I Mania. Currently, two atypical antipsychotic drugs, Risperdal and Abilify, are approved for treatment of schizophrenia and bipolar disorder in the pediatric population. In response to the Agency’s written request (original 11/30/2001; amended 4/9/02, 7/3/02, 5/7/04, 6/29/05), the sponsor conducted clinical trials for two indications: schizophrenia (F1D-MC-HGIN) and bipolar disorder (F1D-MC-HGIU) in adolescents, and submitted the study results to the above referenced supplemental NDA on 10/30/2006.
    [Show full text]
  • Package Leaflet: Information for the Patient Depixol® 20 Mg/Ml Solution
    Package leaflet: Information for the patient Depixol® 20 mg/ml solution for injection flupentixol decanoate Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again • If you have any further questions, ask your doctor, pharmacist or nurse • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Depixol Injection is and what it is used for 2. What you need to know before Depixol Injection is given 3. How Depixol Injection is given 4. Possible side effects 5. How to store Depixol Injection 6. Contents of the pack and other information 1. What Depixol Injection is and what it is used for The name of your medicine is Depixol 20 mg/ml solution for injection (called Depixol Injection in this leaflet). Depixol Injection contains the active substance flupentixol decanoate. Depixol Injection belongs to a group of medicines known as antipsychotics (also called neuroleptics). These medicines act on nerve pathways in specific areas of the brain and help to correct certain chemical imbalances in the brain that are causing the symptoms of your illness. Depixol Injection is used for the treatment of schizophrenia and other psychoses. Your doctor, however, may prescribe Depixol Injection for another purpose.
    [Show full text]
  • Association of Selective Serotonin Reuptake Inhibitors with the Risk for Spontaneous Intracranial Hemorrhage
    Supplementary Online Content Renoux C, Vahey S, Dell’Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published online December 5, 2016. doi:10.1001/jamaneurol.2016.4529 eMethods 1. List of Antidepressants for Cohort Entry eMethods 2. List of Antidepressants According to the Degree of Serotonin Reuptake Inhibition eMethods 3. Potential Confounding Variables Included in Multivariate Models eMethods 4. Sensitivity Analyses eFigure. Flowchart of Incident Antidepressant (AD) Cohort Definition and Case- Control Selection eTable 1. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 2. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 3. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs. eTable 4. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 5. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 6. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 eMethods 1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • New Zealand Data Sheet
    1 PARNATE tranylcypromine film-coated tablets 10 mg New Zealand Data Sheet 1 PARNATE® (10 MG FILM-COATED TABLETS) PARNATE 10 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Parnate 10 mg film-coated tablets: each tablet contains tranylcypromine sulfate equivalent to 10 mg of tranylcypromine. Excipients with known effect: each tablet contains sucrose 6 mg. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Parnate 10 mg film-coated tablets contain "geranium rose" coloured, biconvex, film-coated tablets. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. It is not recommended for use in mild depressive states resulting from temporary situational difficulties. 4.2 Dose and method of administration Adults Begin with 20 mg a day given as 10 mg in the morning and 10 mg in the afternoon. If there is no satisfactory response after two weeks, add one more tablet at midday. Continue this dosage for at least a week. A dosage of 3 tablets a day should only be exceeded with caution. When a satisfactory response is established, dosage may be reduced to a maintenance level. Some patients will be maintained on 20 mg per day, some will need only 10 mg daily. If no improvement occurs, continued administration is unlikely to be beneficial. 1 2 PARNATE tranylcypromine film-coated tablets 10 mg When given together with a tranquilliser, the dosage of Parnate is not affected. When the medicine is given concurrently with electroconvulsive therapy, the recommended dosage is 10 mg twice a day during the series and 10 mg a day afterwards as maintenance therapy.
    [Show full text]
  • Flupentixol Compositions
    (19) & (11) EP 2 374 450 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 12.10.2011 Bulletin 2011/41 A61K 9/20 (2006.01) A61K 47/40 (2006.01) A61K 45/06 (2006.01) A61K 31/496 (2006.01) (2006.01) (2006.01) (21) Application number: 10159137.8 A61K 31/135 A61P 25/22 A61P 25/24 (2006.01) A61P 25/18 (2006.01) (22) Date of filing: 06.04.2010 (84) Designated Contracting States: (72) Inventor: Olsen, Flemming, Enok AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 3450, Allerød (DK) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR Remarks: Designated Extension States: Amended claims in accordance with Rule 137(2) AL BA ME RS EPC. (71) Applicant: H. Lundbeck A/S 2500 Valby (DK) (54) Flupentixol compositions (57) Compositions comprising flupentixol and cyclodextrin are provided. EP 2 374 450 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 374 450 A1 Description Field of invention 5 [0001] Flupentixol is an antipsychotic of the thioxanthene group. Flupentixol has the structure depicted below 10 15 and the systematic name 2-(4-{3-[2-trifluoromethyl-thioxanthen-(9E)-ylidene]-propyl}-piperazin-1-yl)-ethanol. The com- pound was first disclosed in the GB patent 925538 to Smith Kline & French Laboratories in 1963 and said to have e.g. tranquilising and general central nervous system depressant activity. Flupentixol has been marketed as the dihydro- 20 chloride acid salt of the mixed (E)(Z) isomers in tablet form and in solution (Fluanxol®) and also as the (Z) isomer decanoate ester in injectable depot formulations (Depixol®).
    [Show full text]